文献速递胸部肿瘤

解析KRASG12D突变非小细胞肺癌的临床病理、基因组与免疫表型相关性

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2022-07-22

研究汇总四家中心2327例KRAS突变NSCLC,其中15%(n=354)为KRASG12D。相比KRASnon-G12D,KRASG12D吸烟量更低、从不吸烟者更多、PD-L1 TPS与TMB更低、瘤内及总CD8+PD1+ T细胞更少;接受PD-(L)1单药治疗时ORR更差、PFS与OS更短,而化疗联合免疫治疗未见显著差异。

要点

  • KRASG12D占KRAS突变NSCLC的15%(354/2327),中位吸烟量22.5包年,从不吸烟者占22%。
  • KRASG12D的PD-L1 TPS中位1%、TMB中位8.4 mt/Mb,均低于KRASnon-G12D。
  • PD-(L)1单药治疗时KRASG12D的ORR 15.8% vs 28.4%,PFS HR 1.51、OS HR 1.45。

核心结论

  • KRASG12D肺癌具有区别于其他KRAS突变肺癌的临床、基因组和免疫特征,且对PD-(L)1阻断治疗结局更差。
  • 作者认为KRASG12D肺癌的药物开发须考虑这些差异。

研究设计与样本

  • 从Dana-Farber癌症研究所、Memorial Sloan Kettering癌症中心、MD Anderson癌症中心和伦敦帝国学院收集KRAS突变NSCLC患者的临床病理与基因组信息。
  • 在DFCI有可用组织的样本子集中进行CK7、PD-1、PD-L1、Foxp3和CD8多重免疫荧光检测。
  • 按KRAS突变亚型分析接受PD-(L)1抑制±化疗的临床结局。

主要发现

  • 2327例KRAS突变NSCLC中15%(n=354)为KRASG12D。
  • KRASG12D较KRASnon-G12D包年吸烟史更低(中位22.5包年 vs 30.0包年,P<0.0001),从不吸烟者更富集(22% vs 5%,P<0.0001)。
  • KRASG12D的PD-L1 TPS更低(中位1% vs 5%,P<0.01),TMB更低(中位8.4 vs 9.9 mt/Mb,P<0.0001)。
  • 在接受多重免疫荧光检测的样本中,KRASG12D的瘤内及总CD8+PD1+ T细胞更低(P<0.05)。
  • 850例接受PD-(L)1为基础治疗的晚期KRAS突变NSCLC中,KRASG12D较KRASnon-G12D的ORR更差(15.8% vs 28.4%,P=0.03),PFS HR 1.51(95%CI 1.45-2.00,P=0.003),OS HR 1.45(95%CI 1.05-1.99,P=0.02)。

临床怎么用

  • 作者认为KRASG12D肺癌的药物开发将须考虑其独特的临床、基因组和免疫特征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous outcomes, driven by differences in underlying biology shaped by co-mutations. In contrast to KRASG12C NSCLC, KRASG12D NSCLC is associated with low/never-smoking status and is largely uncharacterized. PATIENTS AND METHODS: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype. RESULTS: Of 2327 patients with KRAS-mutated (KRASMUT) NSCLC, 15% (n = 354) harbored KRASG12D. Compared to KRASnon-G12D NSCLC, KRASG12D NSCLC had a lower pack-year (py) smoking history (median 22.5 py versus 30.0 py, P < 0.0001) and was enriched in never smokers (22% versus 5%, P < 0.0001). KRASG12D had lower PD-L1 tumor proportion score (TPS) (median 1% versus 5%, P < 0.01) and lower tumor mutation burden (TMB) compared to KRASnon-G12D (median 8.4 versus 9.9 mt/Mb, P < 0.0001). Of the samples which underwent multiplexed immunofluorescence, KRASG12D had lower intratumoral and total CD8+PD1+ T cells (P < 0.05). Among 850 patients with advanced KRASMUT NSCLC who received PD-(L)1-based therapies, KRASG12D was associated with a worse objective response rate (ORR) (15.8% versus 28.4%, P = 0.03), progression-free survival (PFS) [hazard ratio (HR) 1.51, 95% confidence interval (CI) 1.45-2.00, P = 0.003], and overall survival (OS; HR 1.45, 1.05-1.99, P = 0.02) to PD-(L)1 inhibition alone but not to chemo-immunotherapy combinations [ORR 30.6% versus 35.7%, P = 0.51; PFS HR 1.28 (95%CI 0.92-1.77), P = 0.13; OS HR 1.36 (95%CI 0.95-1.96), P = 0.09] compared to KRASnon-G12D. CONCLUSIONS: KRASG12D lung cancers harbor distinct clinical, genomic, and immunologic features compared to other KRAS-mutated lung cancers and worse outcomes to PD-(L)1 blockade. Drug development for KRASG12D lung cancers will have to take these differences into account.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Ricciuti B, Alessi JV, Elkrief A, et al. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022. PMID: 35872166. doi:10.1016/j.annonc.2022.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。